Eculizumab for paroxysmal nocturnal hemoglobinuria: a review of clinical and cost-effectiveness
Ho C, Spry C
Record ID 32011001310
English
Authors' recommendations:
The limited evidence that was identified suggests eculizumab is more effective than standard care in the treatment of PNH. Newer treatment modalities, such as addition of erythropoietin treatment following complement inhibition with eculizumab in patients with PNH19 could further enhance patients’ outcomes. Considering a conventional threshold of US$50,000 per ICER, eculizumab may not be deemed cost-effective despite a substantial budget impact that the use of eculizumab could provide to health care.
Details
Project Status:
Completed
URL for project:
http://www.cadth.ca/media/pdf/htis/L0053%20Eculizumab%20for%20Paroxysmal%20Nocturnal%20Hemoglobinuria%20final.pdf
Year Published:
2008
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Hemoglobinuria, Paroxysmal
- Antibodies, Monoclonal, Humanized
- Complement Inactivating Agents
- Cost-Effectiveness Analysis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.